I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)
Differentiated Thyroid Carcinoma
About this trial
This is an interventional treatment trial for Differentiated Thyroid Carcinoma focused on measuring Differentiated thyroid carcinoma, PET/CT, Radioiodine Remnant Ablation, I-124, Quality of life
Eligibility Criteria
Inclusion Criteria common for all study subjects prior to randomisation:
- Histologically confirmed new diagnosis of DTC (including Hürthle-cell carcinoma)
- Age 18-80 years
- Performance Status of 0-2
- Tumor stage T1b to T4 with the possibility of lymph node involvement and distant metastasis according to the [TNM] staging system
- One- or two stage thyroidectomy, with or without central lymph node dissection
- Patient´s written informed consent
- Ability to comply with the protocol procedures
Exclusion criteria for all study subjects prior to randomisation:
- Anaplastic or medullary carcinoma
- History of prior malignancy within the past 5 years with limited life-time expectancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years.
- Positive pregnancy test or breast feeding
- Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- Recent iodine contamination
After Randomisation
I-124 arm:
A: Inclusion criteria for no remnant ablation (low risk DTC):
- Stage I (according to AJCC, ref. 1,33) papillary or follicular carcinoma with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0)
- I-124 uptake only in thyroid bed
- Absence of aggressive malignant histologic subtypes, including tall-cell, insular, poorly differentiated and diffuse sclerosing thyroid cancer
B: Inclusion criteria for remnant ablation (high risk DTC):
- All other [TNM] stages (stage II to stage IV C)
- Presence of aggressive malignant histologic subtypes, including tall-cell, insular, poorly differentiated and diffuse sclerosing thyroid cancer
- I-124 uptake in and outside thyroid bed
Standard arm:
-Standard I-131 ablation concept as defined for all T1b to T4 subjects.
Sites / Locations
- Clinic of Nuclear Medicine, University Clinic EssenRecruiting
- University Clinic WürzburgRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Radioiodine
I-124
Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.